BCRX vs FRT · rev $374.7M vs rev $1.28B
BioCryst Pharmaceuticals Inc (BCRX) versus FRT (FRT) — a side-by-side from cached financials, not a winner call.
BioCryst Pharmaceuticals Inc (BCRX) is a drug manufacturers - specialty & generic company listed on US.
FRT (FRT) common stock.
Latest reported BCRX revenue for 2026-06-30 was $374.7M. Net income was -$643.4M. BCRX currently screens at market cap $1.83B.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
BCRX currently screens at market cap $1.83B. FRT currently screens at market cap $0.
Not investment advice. Open the BCRX and FRT stock pages for the full models.
Not investment advice.